Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Hinrichs Website

Christian S. Hinrichs, M.D.

Selected Publications

1)  Hinrichs CS, Rosenberg SA.
Exploiting the curative potential of adoptive T-cell therapy for cancer.
Immunol. Rev. 257: 56-71, 2014.
[Journal]
2)  Turcotte S, Gros A, Hogan K, Tran E, Hinrichs CS, Wunderlich JR, Dudley ME, Rosenberg SA.
Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy.
J. Immunol. 191: 2217-25, 2013.
[Journal]
3)  Hinrichs CS, Restifo NP.
Reassessing target antigens for adoptive T-cell therapy.
Nat. Biotechnol. 31: 999-1008, 2013.
[Journal]
4)  Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, Borman ZA, Kerkar SP, Scott CD, Finkelstein SE, Rosenberg SA, Restifo NP.
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Clin. Cancer Res. 17: 5343-52, 2011.
[Journal]
5)  Kerkar SP, Sanchez-Perez L, Yang S, Borman ZA, Muranski P, Ji Y, Chinnasamy D, Kaiser AD, Hinrichs CS, Klebanoff CA, Scott CD, Gattinoni L, Morgan RA, Rosenberg SA, Restifo NP.
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
J. Immunother. 34: 343-52, 2011.
[Journal]
6)  Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, Klebanoff CA, Johnson LA, Kerkar SP, Yang S, Muranski P, Palmer DC, Scott CD, Morgan RA, Robbins PF, Rosenberg SA, Restifo NP.
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.
Blood. 117: 808-14, 2011.
[Journal]
7)  Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA.
A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas.
Cancer Res. 70: 3027-33, 2010.
[Journal]
8)  Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, Sanchez-Perez L, Muranski P, Kern SJ, Logun C, Palmer DC, Ji Y, Reger RN, Leonard WJ, Danner RL, Rosenberg SA, Restifo NP.
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Proc. Natl. Acad. Sci. U.S.A. 106: 17469-74, 2009.
[Journal]
9)  Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NP.
Type 17 CD8+ T cells display enhanced antitumor immunity.
Blood. 114: 596-9, 2009.
[Journal]
10)  Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP.
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.
Nat. Med. 15: 808-13, 2009.
[Journal]
Click Here to View Expanded Bibliography.

This page was last updated on 4/28/2014.